A meta-analysis revealed that VEGF signaling pathway inhibitors significantly raise the odds of hypertension, cardiac ischemia, arterial thromboembolism, and cardiac dysfunction by 5.3, 2.8, 1.5, and 1.4 times, respectively. This evidence concerns the gene VEGFA and Hypertension.